• Explore /
  • Poster
  • / Phase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC).

Phase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC).

Abstract Poster

Authors

Bernard Tawfik

Bernard Tawfik

University of Texas Southwestern Medical Center, Dallas, TX

Bernard Tawfik , David E. Gerber , Barbara Burtness , Randall S. Hughes , Larry L. Myers , Baran D. Sumer , John Truelson , Tobin Joel Strom , Pamela Kurian , Sehresh Saleem , Jean Pearson , Hong Zhu , Saad A. Khan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Other Head and Neck Cancer (Salivary, Thyroid)

Clinical Trial Registration Number

NCT02289144

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS6098)

DOI

10.1200/JCO.2017.35.15_suppl.TPS6098

Abstract #

TPS6098

Poster Bd #

82a

Abstract Disclosures

Similar Posters

Poster

2022 ASCO Annual Meeting

Abemaciclib in metastatic or locally advanced anaplastic thyroid cancer.

Abemaciclib in metastatic or locally advanced anaplastic thyroid cancer.

First Author: Vishesh Khanna

First Author: Shao Zhimin

First Author: Camila Bragança Xavier

First Author: William Kevin Kelly